The First People's Hospital of Changzhou
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1918-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.czfph.com/en
Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas
Phase 1
Not yet recruiting
- Conditions
- Cytokine-Induced Killer CellsMilignant Gliomas
- Interventions
- Biological: CIKDrug: Temozolomide
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 80
- Registration Number
- NCT02494804
The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
Phase 2
Active, not recruiting
- Conditions
- Adenocarcinoma of Lung
- Interventions
- Biological: Cytokine-Induced Killer CellsDrug: Apatinib
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 400
- Registration Number
- NCT02493582
Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Biological: DC-CIK ImmunotherapyDrug: Capecitabine Monotherapy
- First Posted Date
- 2015-07-08
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 400
- Registration Number
- NCT02491697
CIK in Treating Patients With Esophageal Cancer
Phase 2
Not yet recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Biological: Cytokine-induced Killer Cells
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 2000
- Registration Number
- NCT02490735
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer
Phase 2
Active, not recruiting
- Conditions
- Cervical Cancer
- Interventions
- Procedure: Radiofrequency ablationBiological: Cytokine-induced killer cells
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 10
- Registration Number
- NCT02490748
CIK in Treating Patients With Bladder Cancer
Phase 2
Active, not recruiting
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Biological: Cytokine-induced Killer Cells
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 1500
- Registration Number
- NCT02489890
The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer
Phase 2
Active, not recruiting
- Conditions
- Colorectal Neoplasms
- Interventions
- Biological: Cytokine-Induced Killer Cells
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 1200
- Registration Number
- NCT02487992
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Ovarian Carcinoma
- Interventions
- Procedure: Radiofrequency ablationBiological: Cytokine-induced killer cells
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 50
- Registration Number
- NCT02487693
DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating
Phase 2
Not yet recruiting
- Conditions
- Renal Neoplasma
- Interventions
- Biological: IL-2/IFN-αBiological: DC-CIK
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 1200
- Registration Number
- NCT02487550
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
Phase 2
Active, not recruiting
- Conditions
- Stomach Neoplasms
- Interventions
- Biological: Cytokine-Induced Killer CellsDrug: Apatinib
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 80
- Registration Number
- NCT02485015
© Copyright 2025. All Rights Reserved by MedPath